moxonidine inn newgeneration receptor agonist antihypertensive drug licensed treatment mild moderate essential may role thiazides betablockers ace inhibitors calcium channel blockers appropriate failed control blood pressure addition demonstrates favourable effects parameters insulin resistance syndrome apparently independent blood pressure reduction also growth hormone manufactured solvay pharmaceuticals acquired abbott brand name physiotens moxon moxonidine selective agonist imidazoline receptor subtype receptor subtype found rostral ventrolateral pressor ventromedial depressor areas medulla oblongata moxonidine therefore causes decrease sympathetic nervous system activity therefore decrease blood pressure compared older centralacting antihypertensives moxonidine binds much greater affinity imidazoline contrast clonidine binds receptors near equal affinity moxonidine affinity times greater compared clonidine four times addition moxonidine may also promote sodium excretion improve insulin resistance glucose tolerance protect hypertensive target organ damage kidney disease cardiac hypertrophy animal models insulin resistance moxonidine striking effects development insulin resistance hyperinsulinaemia impaired glucose homeostasis given importance insulin resistance risk factor cardiovascular disease considerable relevance shown improve insulin sensitivity contraindicated past history angioedema heart conduction disorders eg sick sinus syndrome second thirddegree heart block bradycardia severe heart failure coronary artery disease also raynauds syndrome intermittent claudication epilepsy depression parkinsons disease glaucoma use pregnancy discouraged moxonidine passes breast milk moxonidine avoided patients moderate severe renal impairment abrupt discontinuation drug also avoided concomitant treatment beta blocker stopped beta blocker discontinued first moxonidine days alcohol may potentiate hypotensive effects moxonidinemedical citation needed excess mortality seen patients symptomatic heart failure moxcon however moxcon trial utilised high dose mg daily well normal dose mg daily noteworthy side effects include dry mouth headache fatigue dizziness intermittent facial oedema nausea sleep disturbances rarely sedation asthenia vasodilatation rarely skin reactions routine toxicology studies provided evidence moxonidine teratogenic mutagenic carcinogenic potential evidence found serious adverse effects organs organ systems drug shown deleterious effects perinatal postnatal growth development concomitant administration moxonidine thiazide diuretic hydrochlorothiazide gave synergistic antihypertensive effect httpsenwikipediaorgwikimoxonidine